商业化 CAR-T 细胞治疗后的 T 细胞淋巴瘤与第二原发恶性肿瘤风险
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
63.3分
★★★☆☆
站内排序·非疗效
ALL SOURCES
T cell lymphoma and secondary primary malignancy risk after commercial CAR T cell therapy.
NKTR-255, a polymer-conjugated IL-15, synergizes with CAR-T cell therapy to activate endogenous anti-tumor immunity and improve tumor control.
共 2 条
MEMBER ACCOUNT
登录成功会直接打开下一页。